Loxo Oncology Inc  

(Public, NASDAQ:LOXO)   Watch this stock  
Find more results for LOXO
+4.49 (4.30%)
Real-time:   10:20AM EST
NASDAQ real-time data - Disclaimer
Currency in USD
Range 104.92 - 108.82
52 week 40.01 - 110.57
Open 104.92
Vol / Avg. 10,622.00/340,973.00
Mkt cap 3.26B
P/E     -
Div/yield     -
EPS -5.81
Shares 29.94M
Beta 2.56
Inst. own 108%
Mar 13, 2018
Loxo Oncology Inc at Cowen Health care Conference - 10:00AM EDT - Add to calendar
Mar 5, 2018
Q4 2017 Loxo Oncology Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 30, 2017
Loxo Oncology Inc at Evercore ISI Biopharma Catalyst/Deep Dive Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -66.54% -47.82%
Return on average equity -68.77% -50.85%
Employees 47 -
CDP Score - -


281 Tresser Blvd Fl 9
STAMFORD, CT 06901-3238
United States - Map
+1-203-6533880 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Loxo Oncology, Inc. is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company's pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. Larotrectinib, formerly referred to as LOXO-101, is an oral, selective inhibitor of the tropomyosin receptor kinase (TRK) family in development for the treatment of tumors with TRK fusions. TRK fusions have been implicated in various tumor types, such as lung cancer, head and neck cancer, melanoma, colorectal cancer, sarcoma, and breast cancer. LOXO-195 is a drug candidate in preclinical development. It was designed as a second-generation TRK inhibitor intended to address predicted acquired resistance mechanisms resulting from therapy with a first-generation TRK inhibitor, such as larotrectinib, or multikinase inhibitors with anti-TRK activity.

Officers and directors

Joshua H. Bilenker M.D. President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Jennifer Burstein CPA Vice President - Finance
Age: 45
Bio & Compensation  - Reuters
Jacob S. Van Naarden Chief Business Officer
Age: 32
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Director
Age: 46
Bio & Compensation  - Reuters
Lori A. Kunkel M.D. Director
Age: 59
Bio & Compensation  - Reuters
Steven A. Elms Independent Director
Age: 53
Bio & Compensation  - Reuters
Alan Fuhrman Independent Director
Age: 60
Bio & Compensation  - Reuters
Steven D. Harr M.D. Independent Director
Age: 46
Bio & Compensation  - Reuters